Prospective randomised study comparing luteal phase support in in-vitro fertilisation/intracytoplasmic sperm injection patients for three weeks versus seven weeks from day of positive pregnancy test

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN88722916

Enrollment

400

Registered

2007-01-25

Start date

2006-12-20

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility patients treated by IVF/ICSI Pregnancy and Childbirth Infertility

Interventions

All patients receive intramuscular (IM) progesterone 50 mg daily from day of oocyte retrieval and continue for three weeks from day of positive ß-hCG test, i.e. day of first ultrasound. Patients are

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients undergoing IVF/intra-cytoplasmic sperm injection (ICSI) 2. Aged less than 39 years 3. Having at least three high quality embryos

Exclusion criteria

Exclusion criteria: Intra-cytoplasmic sperm injection (ICSI) using surgically retrieved sperm.

Design outcomes

Primary

Measure	Time frame
Miscarriage rate in the first trimester	—

Secondary

Measure	Time frame
1. Bleeding episodes in the first trimester 2. Adverse reactions to progesterone	—

Countries

Egypt

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026